Biomarkers such as microsatellite instability-high (MSI-H), mismatch repair deficiency (dMMR), high tumor mutational burden (TMB ≥ 10 mutations/megabase), and PD-L1 expression are approved by the FDA for clinical use [103,104,105,106]. This evidence concerns the gene CD274 and neoplasm.